author-photo

Daniel C. Howey

Eli Lilly and Company

27

Papers

1265

Citations

Citation Trend

Filter By

Papers (21) Sort By

Journal Conference Others

Steady-state pharmacokinetics and glucodynamics of the novel, long-acting basal insulin LY2605541 dosed once-daily in patients with type 2 diabetes mellitus.

2014 Diabetes, Obesity and Metabolism
Show All
- Source
- Cite
- Save
Citations (54)
Response to Comment on: Bergenstal et al. A Randomized, Controlled Study of Once-Daily LY2605541, a Novel Long-Acting Basal Insulin, Versus Insulin Glargine in Basal Insulin–Treated Patients With Type 2 Diabetes. Diabetes Care 2012;35:2140–2147

2013 Diabetes Care
Show All
- Source
- Cite
- Save
Citations (1)
Better Glycemic Control and Weight Loss With the Novel Long-Acting Basal Insulin LY2605541 Compared With Insulin Glargine in Type 1 Diabetes: A randomized, crossover study

2013 Diabetes Care
Show All
- Source
- Cite
- Save
Citations (90)
P1146 Pharmacocinétique (PK) et pharmacodynamique (PD) à l’état d’équilibre du nouvel analogue lent de l’insuline LY2605541 en administration quotidienne (QD) chez des patients diabétiques de type 2 (DT2) - presented at American Diabetes Association (ADA) 2012 - permission copyright ADA

2013 Diabetes & Metabolism
Show All
- Source
- Cite
- Save
Citations (0)
A Randomized, Controlled Study of Once-Daily LY2605541, a Novel Long-Acting Basal Insulin, Versus Insulin Glargine in Basal Insulin–Treated Patients With Type 2 Diabetes

2012 Diabetes Care
Show All
- Source
- Cite
- Save
Citations (109)
Potent and Selective PPAR-α Agonist LY518674 Upregulates Both ApoA-I Production and Catabolism in Human Subjects With the Metabolic Syndrome

2009 Arteriosclerosis, Thrombosis, and Vascular Biology
Show All
- Source
- Cite
- Save
Citations (38)
Effects of a potent and selective PPAR-α agonist in patients with atherogenic dyslipidemia or hypercholesterolemia : Two randomized controlled trials

2007 JAMA
Show All
- Source
- Cite
- Save
Citations (118)
Abstract 681: Treatment With A Potent & Selective PPAR-{alpha} Agonist LY518674 Significantly Increases ApoA-I and ApoA-II Production Rates In Patients With Metabolic Syndrome Despite No Change In HDL

2007 Circulation
Show All
- Source
- Cite
- Save
Citations (1)
Relating Glucose Clamp Profiles to Reduction of Blood Glucose After Insulin Administration

2004 Diabetes Technology & Therapeutics
Show All
- Source
- Cite
- Save
Citations (2)
Why Rate of Absorption Inferences in Single Dose Bioequivalence Studies are Often Inappropriate

1998 Pharmaceutical Research
Show All
- Source
- Cite
- Save
Citations (10)